Revolution Medicines, Inc.

RVMD

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Jun 15, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
Gemcitabine	Phase 3	Pancreatic Cancer	-
daraxonrasib	Phase 3	NSCLC (Non-small Cell Lung Cancer)	-
RMC-4630	Phase 2	Non-Small Cell Lung Cancer	-
RMC-6236	Phase 2	Colorectal Cancer	-
RMC-6291	Phase 2	Non-Small Cell Lung Cancer, NSCLC	-
Cobimetinib	Phase 2	Solid Tumor	-

Catalyst Timeline

2 upcoming, 0 past

⭐Phase 3Next

June 2026~Gemcitabine

Primary completion for Gemcitabine trial (NCT06625320) in Pancreatic Cancer

⭐Phase 3

June 2026~RMC-6236

Primary completion for RMC-6236 trial (NCT06625320) in Pancreatic Cancer

Regulatory Approvals

RVMD News